文献速递其他结缔组织病

从混合性结缔组织病谱系解读IPAF、VEDOSS与结缔组织病分类

Unravelling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum.
PubMed 文献 · RMD Open · 2025-10-23

诊断时满足IPAF或VEDOSS标准均不能预测向SSc进展,而抗磷脂抗体和低补体C3和/或C4可预测向SLE进展。

要点

  • MCTD诊断时满足IPAF标准者进展为dCTD的比例与不满足者无显著差异(p=0.09)。
  • MCTD诊断时满足VEDOSS标准者进展为SSc的比例与不满足者无显著差异(p=0.8)。
  • 抗磷脂抗体和低C3和/或C4可预测MCTD向SLE进展。

核心结论

  • MCTD诊断时满足IPAF和/或VEDOSS标准不能预测向SSc进展,而抗磷脂抗体和低C3和/或C4可预测向SLE进展。
  • 原文提示MCTD患者应被排除在IPAF和VEDOSS之外。

研究设计与样本

  • 使用IPAF、VEDOSS及当前dCTD分类标准对患者进行分类。

主要发现

  • 诊断时38例(11.7%)满足IPAF标准,其中15例(39.5%)进展为dCTD,而不满足IPAF标准者中75例(26.2%)进展为dCTD(p=0.09)。
  • 诊断时293例(90.4%)满足VEDOSS标准,其向SSc进展的比例与不满足VEDOSS标准者无显著差异(46例(15.7%) vs 4例(12.9%);p=0.8)。
  • 基线时SSc分类标准未预测向SSc evolution,而抗磷脂抗体和低C3和/或C4分别预测向SLE evolution(p=0.01和p=0.04)。

关键数值与推荐

  • 抗磷脂抗体预测向SLE evolution的p=0.01;低C3和/或C4预测向SLE evolution的p=0.04。

临床怎么用

  • 在MCTD诊断时,IPAF和VEDOSS标准的满足情况未显示可预测向SSc进展。
  • 抗磷脂抗体和低C3和/或C4可预测MCTD向SLE进展。
  • 原文建议MCTD患者应被排除在IPAF和VEDOSS之外。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mixed connective tissue disease (MCTD) has long been debated as an early nonspecific phase/symptom of differentiated connective tissue diseases (dCTD), similarly to interstitial pneumonia with autoimmune features (IPAF) and very early diagnosis of systemic sclerosis (SSc) (VEDOSS). OBJECTIVE: We aimed to evaluate the predictive value of IPAF, VEDOSS and dCTD classification criteria variables in MCTD patients. METHODS: We conducted an observational study within the French MCTD cohort. IPAF, VEDOSS and current dCTD classification criteria were used to classify patients. RESULTS: Three hundred and twenty-four MCTD patients were included and followed for 8 (3.3-13) years. Among them, 111 (34.3%) progressed into a dCTD, that is, 50 (15.4%) SSc, 40 (12.3%) systemic lupus erythematosus (SLE) and 11 (3.4%) Sjögren's disease. At diagnosis, 38 (11.7%) patients fulfilled IPAF criteria, among which 15 (39.5%) progressed into a dCTD (vs 75 (26.2%) in patients who did not fulfil IPAF criteria; p=0.09). At diagnosis, 293 (90.4%) patients fulfilled VEDOSS criteria but did not progress significantly more frequently to SSc than MCTD patients without VEDOSS criteria (46 (15.7%) vs 4 (12.9%); p=0.8). At baseline, SSc classification criteria did not predict evolution toward SSc, whereas antiphospholipid antibodies and low C3 and/or C4 were predictive of an evolution toward SLE (p=0.01 and p=0.04, respectively). CONCLUSION: At MCTD diagnosis, fulfilment of IPAF and/or VEDOSS criteria was not predictive of evolution toward SSc, whereas antiphospholipid antibodies and low C3 and/or C4 were predictive of an evolution toward SLE. This suggests that MCTD patients should be excluded from IPAF and VEDOSS.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Chevalier K, Thoreau B, Michel M, et al. Unravelling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum. RMD Open. 2025. PMID: 41130746. doi:10.1136/rmdopen-2025-006145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。